LRMR Soared
LRMR (LRMR:NASDAQ) jumped higher at $10.34, representing a gain of 23.7%. On Tue, May 11, 2021, LRMR:NASDAQ touched a New 2-Week Low of $8.36. The stock got featured on our News Catalysts scanner on Tue, May 11, 2021 at 07:34 AM in the 'BIOTECH' category. From Tue, Apr 27, 2021, the stock recorded 50.00% Up Days and 36.36% Green Days
About LRMR (LRMR:NASDAQ)
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Top 10 Gainers:
- REVH (REVH:NASDAQ), 2074.47%
- Curis, Inc. (CRIS:NASDAQ), 65.51%
- LHDX (LHDX:NASDAQ), 44.2%
- Autolus Therapeutics plc (AUTL:NASDAQ), 35.47%
- Summit Wireless Technologies, Inc. (WISA:NASDAQ), 31.01%
- Second Sight Medical Products, Inc. (EYES:NASDAQ), 27.6%
- ShotSpotter, Inc. (SSTI:NASDAQ), 25.39%
- Barnwell Industries, Inc. (BRN:NYSEMKT), 23.97%
- LRMR (LRMR:NASDAQ), 23.68%
- Ra Medical Systems, Inc. (RMED:NYSE), 18.07%